curasan AG’s Restructuring


Gleiss Lutz has provided extensive advice to curasan AG, Kleinostheim on restructuring.

curasan’s shares are admitted to trading on the Frankfurt Stock Exchange’s regulated market.

In addition to new appointments to the management board and supervisory board, the restructuring includes various capital increases. Most recently, these have included a successful increase of the company’s share capital to EUR 9,065,873 while maintaining shareholders’ subscription rights, as resolved upon by the company’s annual general meeting. Before this rights offering was made, the company’s share capital was reduced by EUR 12,254,892 to EUR 6,127,446, merging shares at a ratio of three to one, in order to cover losses. Gleiss Lutz also advised curasan on this measure.

curasan develops, produces and markets biomaterials and other medical devices in the area of bone and tissue regeneration.

curasan was advised by the following team of Gleiss Lutz lawyers: Dr. Stephan Aubel (Picture), Dr. Detlef Bauer (both partners, corporate and capital markets, Frankfurt), Dr. Doris-Maria Schuster (partner, employment, Frankfurt/Hamburg), Dr Matthias Tresselt (partner, restructuring, Stuttgart), Alexander Gebhardt, Jan-Rasmus Roßkamp, Dr. Walter Andert and Jannik Hermes (all corporate and capital markets, Frankfurt).

Involved fees earner: Walter Andert – Gleiss Lutz; Stephan Aubel – Gleiss Lutz; Detlef Bauer – Gleiss Lutz; Alexander Gebhardt – Gleiss Lutz; Jannik Hermes – Gleiss Lutz; Jan-Rasmus Roßkamp – Gleiss Lutz; Doris-Maria Schuster – Gleiss Lutz; Matthias Tresselt – Gleiss Lutz;

Law Firms: Gleiss Lutz;

Clients: Curasan AG;